NCT04257578 - Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

August 7, 2025

Study Completion Date

March 1, 2031

Conditions

B-Cell Non-Hodgkin LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaPrimary Mediastinal (Thymic) Large B-Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma

Interventions

DRUG

Acalabrutinib

Given PO

BIOLOGICAL

Axicabtagene Ciloleucel

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle